Selective inhibition by simvastatin of IRF3 phosphorylation and TSLP production in dsRNAchallenged bronchial epithelial cells from COPD donors

20Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background and Purpose Statin treatment may ameliorate viral infection-induced exacerbations of chronic obstructive pulmonary disease (COPD), which exhibit Th2-type bronchial inflammation. Thymic stromal lymphopoietin (TSLP), a hub cytokine switching on Th2 inflammation, is overproduced in viral and dsRNA-stimulated bronchial epithelial cells from COPD donors. Hence, TSLP may be causally involved in exacerbations. This study tests the hypothesis that simvastatin inhibits dsRNA-induced TSLP. Experimental Approach Epithelial cells, obtained by bronchoscopy from COPD (n = 7) and smoker control (n = 8) donors, were grown and stimulated with a viral infection and danger signal surrogate, dsRNA (10 μg·mL-1). Cells were treated with simvastatin (0.2-5 μg·mL-1), with or without mevalonate (13-26 μg·mL-1), or dexamethasone (1 μg·mL-1) before dsRNA. Cytokine expression and production, and transcription factor (IRF3 and NF-κB) activation were determined. Key Results dsRNA induced TSLP, TNF-α, CXCL8 and IFN-β. TSLP was overproduced in dsRNA-exposed COPD cells compared with control. Simvastatin, but not dexamethasone, concentration-dependently inhibited dsRNA-induced TSLP. Unexpectedly, simvastatin acted independently of mevalonate and did not affect dsRNA-induced NF-κB activation nor did it reduce production of TNF-α and CXCL8. Instead, simvastatin inhibited dsRNA-induced IRF3 phosphorylation and generation of IFN-β. Conclusions and Implications Independent of mevalonate and NF-κB, previously acknowledged anti-inflammatory mechanisms of pleiotropic statins, simvastatin selectively inhibited dsRNA-induced IRF3 activation and production of TSLP and IFN-β in COPD epithelium. These data provide novel insight into epithelial generation of TSLP and suggest paths to be exploited in drug discovery aimed at inhibiting TSLP-induced pulmonary immunopathology. © 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.

Cite

CITATION STYLE

APA

Brandelius, A., Mahmutovic Persson, I., Calvén, J., Bjermer, L., Persson, C. G., Andersson, M., & Uller, L. (2013). Selective inhibition by simvastatin of IRF3 phosphorylation and TSLP production in dsRNAchallenged bronchial epithelial cells from COPD donors. British Journal of Pharmacology, 168(2), 363–374. https://doi.org/10.1111/j.1476-5381.2012.02131.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free